Trial Profile
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary) ; Tremelimumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CHESS
- 29 Aug 2023 Status changed from active, no longer recruiting to recruiting.
- 16 Nov 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2026.
- 16 Nov 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Aug 2026.